GlassScriptPhysician profile
Anthony Ryan Russo
NPI 1366890410
$8,458.86
in general payments reported to CMS, 2019-2025
45 companies · $184 in 2025
The $184 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $370 · 2020: $779 · 2021: $964 · 2022: $1,870 · 2023: $2,142 · 2024: $2,149 · 2025: $184.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,350 · Education: $126.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,349.55 |
| Education | $125.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,544.54 | 2020-2025 | Ubrelvy, Qulipta, Vraylar |
| Novo Nordisk INC | $834.25 | 2020-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $731.89 | 2021-2025 | Farxiga, Airsupra, Breztri |
| Lilly USA, LLC | $647.39 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Pfizer INC. | $624.51 | 2019-2024 | |
| Astellas Pharma US INC | $446.48 | 2021-2024 | Veozah |
| Amarin Pharma, INC. | $421.46 | 2019-2023 | |
| Amgen INC. | $385.89 | 2020-2025 | Repatha, Otezla, Otezla |
| Merck Sharp & Dohme LLC | $370.90 | 2019-2024 | Verquvo, Belsomra, Dificid |
| Boehringer Ingelheim Pharmaceuticals, INC. | $344.78 | 2019-2025 | Jardiance, Synjardy, Tradjenta |
| Glaxosmithkline, LLC. | $225.38 | 2019-2024 | Trelegy Ellipta, Arexvy, Shingrix |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $163.92 | 2019-2024 | Xifaxan, Trulance |
| Mylan Specialty L.P. | $152.28 | 2019-2024 | Yupelri |
| Janssen Pharmaceuticals, INC | $147.18 | 2019-2024 | Xarelto |
| Exact Sciences Corporation | $135.88 | 2023-2024 | Cologuard Collection Kit |
Show all 45 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anthony Russo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.